Alexion
121 Seaport Blvd Boston
Boston
MA
02210
United States
Tel: 475-230-2596
Website: http://www.alexion.com/
About Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Company Ownership: Public
Stock Symbol: AZN
Stock Exchange: Nasdaq
715 articles with Alexion
-
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.
5/5/2020
Rowley Law PLLC is investigating potential securities law violations by Portola Pharmaceuticals, Inc. and its board of directors concerning the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. Stockholders will receive $18.00 for each share of Portola Pharmaceuticals stock that they hold.
-
Alexion to Acquire Portola
5/5/2020
Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent
-
Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders.
-
Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)
5/1/2020
Alexion Receives CHMP Positive Opinion for ULTOMIRIS ® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)
-
Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
4/20/2020
Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS ® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 - Global study to enroll approximately 270 adults with COVID-19 and severe pneumonia or acute respiratory distress syndrome - - Company maintains commitment to supplying its medicines to patients for currently approved indications -
-
Clinical Catch-Up: April 6-10
4/13/2020
It was a very busy week for clinical trial news. Here’s a look. -
Alexion to Report First Quarter Results and Provide Update on COVID-19 on Wednesday, May 6th, 2020
4/9/2020
Company Announces 2020 Annual Shareholder Meeting To Be Held Virtually
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
-
Alexion Announces Upcoming Data Presentations at 72nd Annual Meeting of the American Academy of Neurology
3/5/2020
Nine abstracts accepted, including long-term data and subgroup analyses from the Phase 3 PREVENT clinical trial evaluating SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD)
-
Alexion Announces Launch of Alexion Charitable Foundation and Calls for Grantees
2/27/2020
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of the Alexion Charitable Foundation to provide further support for the rare disease community and for local communities which the company serves.
-
Alexion to Present at the 40th Annual Cowen Health Care Conference
2/26/2020
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Cowen Health Care Conference in Boston, MA on Tuesday, March 3rd, 2020 at 9:20 a.m. ET.
-
The company has abandoned the project based on unfavorable early-stage data.
-
Alexion to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2/20/2020
Alexion Pharmaceuticals announced that management will present at the SVB Leerink Global Healthcare Conference in New York, NY on Tuesday, February 25th, 2020 at 9:30 a.m. ET.
-
Alexion Reports Fourth Quarter and Full Year 2019 Results
1/30/2020
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019.
-
Alexion Completes Acquisition of Achillion
1/28/2020
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development platform with the potential to treat numerous additional complement-mediated diseases.
-
UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020
1/24/2020
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time.
-
Clinical Catch-Up: January 13-17
1/20/2020
There were plenty of clinical trial announcements this week. Here's a look. -
Alexion to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020
1/17/2020
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020
-
The company’s chief executive officer, Ludwig Hantson, admits it's a longshot.
-
Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS
1/14/2020
50-week global study to enroll ~350 patients across broad ALS population